达金州通过RXR-γ/PPAR-γ/VEGF-α途径改善CSVD:从转录组测序和网络药理学的见解
Mengna Lv1,2, Xiaolu Yang3, Xiaolu Shi2
1Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Journal of cellular and molecular medicine
|July 19, 2025
概括
达金州 (DQJD) 通过减少炎症和保护神经血管系统来治疗大脑小血管疾病 (CSVD). 它的机制涉及激活RXR-γ/PPAR-γ/VEGF-α通路,改善大脑组织损伤.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 大脑小血管疾病 (CSVD) 是一个重大的临床挑战.
- 作为一种传统中医药,达金州 (DQJD) 对心血管疾病的治疗机制尚未完全理解.
- 研究DQJD的分子通路对于开发有效的CSVD治疗至关重要.
研究的目的:
- 为了阐明大江 (DQJD) 在治疗慢性大脑低 perfusion (CCH) 的分子机制,CSVD的一个模型.
- 确定关键活性成分,基因标和参与DQJD治疗作用的信号通路.
- 验证已识别的途径在改善CSVD相关的病理损伤中的作用.
主要方法:
- 建立了使用双边常见大脑动脉阻塞 (BCCAO) 慢性大脑低 perfusion (CCH) 的老鼠模型.
- 用MRI,HE染色和传输电子显微镜进行了DQJD和治疗效果的评估.
- 采用转录组学 (RNA-seq) 和网络药理学来识别差异表达基因 (DEG) 和途径.
- 通过分子对接,RT-qPCR和西部斑分析验证了关键发现.
主要成果:
- DQJD治疗显著改善了CCH大鼠皮质和海马体的病理损伤.
- RNA-seq确定了46个DEG,网络药理学突出了PPAR/VEGF信号通路.
- 验证证实,RXR-γ/PPAR-γ/VEGF-α通路的激活是DQJD治疗效果的关键机制.
- DQJD减少了炎症因素,并提供了神经血管保护.
结论:
- 大金家 (DQJD) 蒸通过减轻炎症和病理损伤,证明了对脑小血管疾病 (CSVD) 的治疗潜力.
- DQJD的神经保护作用通过RXR-γ/PPAR-γ/VEGF-α信号通路的激活进行介导.
- 这项研究为DQJD在治疗CSVD的临床应用提供了分子基础.
更多相关视频
12:34Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
914
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
182
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
